Soligenix, Inc. (SNGX): Price and Financial Metrics

Soligenix, Inc. (SNGX): $1.97

-0.08 (-3.90%)

POWR Rating

Component Grades













SNGX Stock Summary

  • SOLIGENIX INC's market capitalization of $5,302,547 is ahead of only 1.94% of US-listed equities.
  • SNGX's price/sales ratio is 6.18; that's higher than the P/S ratio of 82.85% of US stocks.
  • The volatility of SOLIGENIX INC's share price is greater than that of 99.14% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to SOLIGENIX INC, a group of peers worth examining would be KOPN, NVCN, PALT, OCFT, and VTVT.
  • SNGX's SEC filings can be seen here. And to visit SOLIGENIX INC's official web site, go to

SNGX Valuation Summary

  • In comparison to the median Healthcare stock, SNGX's EV/EBIT ratio is 98.48% lower, now standing at 0.1.
  • SNGX's price/sales ratio has moved NA NA over the prior 243 months.

Below are key valuation metrics over time for SNGX.

Stock Date P/S P/B P/E EV/EBIT
SNGX 2023-03-24 6.2 5.1 -0.4 0.1
SNGX 2023-03-23 6.2 5.1 -0.4 0.1
SNGX 2023-03-22 6.3 5.2 -0.4 0.1
SNGX 2023-03-21 6.9 5.7 -0.4 0.0
SNGX 2023-03-20 7.2 6.0 -0.4 0.0
SNGX 2023-03-17 7.8 6.5 -0.5 0.0

SNGX Growth Metrics

    Its 3 year price growth rate is now at -46.22%.
  • The 3 year cash and equivalents growth rate now stands at 217.71%.
  • Its 4 year cash and equivalents growth rate is now at 0.83%.
Over the past 15 months, SNGX's revenue has gone down $433,526.

The table below shows SNGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.858496 -12.07723 -14.74866
2022-06-30 0.878554 -11.86238 -15.02721
2022-03-31 0.864738 -10.99324 -14.53752
2021-12-31 0.824268 -11.73962 -12.55097
2021-09-30 0.869409 -12.80922 -13.38736
2021-06-30 1.292022 -12.76004 -11.58997

SNGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SNGX has a Quality Grade of F, ranking ahead of 4.48% of graded US stocks.
  • SNGX's asset turnover comes in at 0.055 -- ranking 317th of 682 Pharmaceutical Products stocks.
  • AVDL, OTIC, and ICPT are the stocks whose asset turnover ratios are most correlated with SNGX.

The table below shows SNGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.055 0.261 -2.934
2021-03-31 0.082 0.296 -9.045
2020-12-31 0.171 0.228 13.842
2020-09-30 0.253 0.205 4.321
2020-06-30 0.353 0.185 4.346
2020-03-31 0.502 0.213 4.558

SNGX Price Target

For more insight on analysts targets of SNGX, see our SNGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.88 Average Broker Recommendation 1.75 (Moderate Buy)

SNGX Stock Price Chart Interactive Chart >

Price chart for SNGX

SNGX Price/Volume Stats

Current price $1.97 52-week high $15.00
Prev. close $2.05 52-week low $1.75
Day low $1.84 Volume 25,200
Day high $2.04 Avg. volume 29,293
50-day MA $4.23 Dividend yield N/A
200-day MA $8.33 Market Cap 5.70M

Soligenix, Inc. (SNGX) Company Bio

Soligenix, Inc. develops therapeutics and vaccines. The Company researches treatments for gastrointestinal Graft-versus-Host disease and cancer, and develops vaccines for military and civilian applications.

SNGX Latest News Stream

Event/Time News Detail
Loading, please wait...

SNGX Latest Social Stream

Loading social stream, please wait...

View Full SNGX Social Stream

Latest SNGX News From Around the Web

Below are the latest news stories about SOLIGENIX INC that investors may wish to consider to help them evaluate SNGX as an investment opportunity.

Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company has submitted a Type A Meeting Request to the United States (U.S.) Food and Drug Administration (FDA) to discuss the contents of a refusal to file (RTF) letter previously issued by the FDA regarding the Company's new drug application (NDA) for HyBryte™ (syn

Yahoo | March 9, 2023

Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks

NEW YORK, NY - (NewMediaWire) - February 16, 2023 - PCG Digital -- As Equatorial Guinea confirms the deaths of nine people in its first outbreak of Marburg virus, Soligenix, Inc.'s (Nasdaq: SNGX) work in developing critical public health solutions has become even more timely. The company has successfully attracted government funding and grants to its programs as it responds to the acute need for effective vaccines to stop virus outbreaks at their source. According to the World Health Organization, Marburg virus can have a fatality rate of up to 88%.

Yahoo | February 16, 2023

OXY Stock Alert: Occidental Petroleum Receives Goldman Sachs Upgrade

Occidental Petroleum (OXY) stock is on the rise Tuesday following an bullish upgrade and new price target from Goldman Sachs.

William White on InvestorPlace | February 14, 2023

Why Is Soligenix (SNGX) Stock Down 27% Today?

Soligenix (SNGX) stock is falling hard on Tuesday with heavy trading after the company's HyBryte cancer drug was rejected by the FDA.

William White on InvestorPlace | February 14, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday!

William White on InvestorPlace | February 14, 2023

Read More 'SNGX' Stories Here

SNGX Price Returns

1-mo -27.57%
3-mo -70.94%
6-mo -69.93%
1-year -82.01%
3-year -92.18%
5-year -93.26%
YTD -70.94%
2022 -31.55%
2021 -48.41%
2020 -11.72%
2019 68.60%
2018 -61.26%

Continue Researching SNGX

Want to see what other sources are saying about Soligenix Inc's financials and stock price? Try the links below:

Soligenix Inc (SNGX) Stock Price | Nasdaq
Soligenix Inc (SNGX) Stock Quote, History and News - Yahoo Finance
Soligenix Inc (SNGX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.989 seconds.